New painkiller injection could cut opioid use after chest surgery

NCT ID NCT03737292

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a long-acting form of the numbing drug bupivacaine (liposomal bupivacaine) provides better pain relief than the standard version after minimally invasive chest surgery. Forty adults undergoing thoracoscopic procedures will receive one of the two drugs injected between their ribs. Researchers will measure drug levels in the blood and track pain, opioid use, and recovery for up to 3 months. The goal is to see if the liposomal version can safely reduce pain and opioid-related complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
liposomal bupivacaine (Exparel) and plain bupivacaine
What this could lead to
If successful, this could lead to better pain management after chest surgery, reducing the need for opioids and their side effects.
What could go wrong
This is a small, early-phase study with only 40 participants, so results may not apply to everyone. The long-term benefits and safety are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAIN, POSTOPERATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Milton S. Hershey Medical Center

    RECRUITING

    Hershey, Pennsylvania, 17033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.